Artículo de revista
Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor
Fecha
2012Registro en:
Biomaterials, Volumen 33, Issue 29, 2018, Pages 7194-7205
01429612
18785905
10.1016/j.biomaterials.2012.06.063
Autor
Prades, Roger
Guerrero, Simón
Araya, Eyleen
Molina, Claudia
Salas, Edison
Zurita, Esther
Selva, Javier
Egea, Gustavo
López-Iglesias, Carmen
Teixidó, Meritxell
Kogan Bocian, Marcelo
Giralt, Ernest
Institución
Resumen
The treatment of Alzheimer's disease and many other brain-related disorders is limited because of the presence of the blood-brain barrier, which highly regulate the crossing of drugs. Metal nanoparticles have unique features that could contribute to the development of new therapies for these diseases. Nanoparticles have the capacity to carry several molecules of a drug; furthermore, their unique physico-chemical properties allow, for example, photothermal therapy to produce molecular surgery to destroy tumor cells and toxic structures. Recently, we demonstrated that gold nanoparticles conjugated to the peptide CLPFFD are useful to destroy the toxic aggregates of β-amyloid, similar to the ones found in the brains of patients with Alzheimer's disease. However, nanoparticles, like many other compounds, have null or very low capacity to cross the blood-brain barrier. In order to devise a strategy to improve drug delivery to the brain, here we introduced the peptide sequence THRPPMWSPVWP in